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748Frailty, from the French frêle
meaning of little resistance, is a
biological syndrome that reﬂects
a state of decreased physiologi-
cal reserve and vulnerability to
stressors (1). Stressors are broadly
classiﬁed as acute or chronic ill-
ness (e.g., myocardial infarction)
or iatrogenic (e.g., cardiac surgery).
When exposed to such stressors,
frail patients are at risk for
marked and often dispropor-
tionate decompensation, adverse
events, procedural complications,
prolonged recovery, functional de-cline, disability, and mortality (2).
Frailty has become a high-priority theme in cardiovascular
medicine due to the aging and increasingly complex nature
of our patients (3). Evolving technical innovations have enabled
clinicians to treat a wider array of patients with devices and
procedures, many of whom were previously regarded as “ineli-
gible” (4,5). Uncertainty regarding individual beneﬁt from such
treatments has been coupledwith growing economic constraints
on healthcare systems, such that the issue of appropriate patient
selection has intensiﬁed. There is an unmet need to optimize
resource allocation to prevent patients from receiving costly but
futile interventions.Leading Toward the Phenotype
of inﬂammatory cells and decline in androgen hormon
osition known as sarcopenia. This detrimental respons
s a vicious cycle of further decline in muscle mass, li
airments in multiple organ systems resulting from ca
nd resiliency to stressors. Other pathophysiological p
ss, physical inactivity, and exhaustiondtermed the pAssessment of frailty is instrumental to reﬁne estimates of
risk and guide patients toward personalized treatment plans
that will maximize their likelihood of a positive outcome.
For example, given 2 heart failure patients with similar
chronological age and comorbidities, the presence of
objectively-measured frailty alerts the clinician that 1 of the
2 patients has a substantially higher risk of mortality and
major morbidity. Furthermore, the frail patient faces a
higher risk from invasive procedures but also a potential
beneﬁt from interventions such as cardiac rehabilitation to
counteract the physical weakness characteristic of frailty.
A critical mass of clinicians, researchers, and policy makers
have embraced the concept of frailty, yet the lack of a sci-
entiﬁc road map to integrate frailty into practice has been a
limiting factor.
The objectives of this state-of-the-art paper are to:
1) summarize the existing body of evidence for frailty in
patients with cardiovascular disease (CVD); 2) offer a
perspective on integrating frailty into current clinical practice;
and 3) point out the knowledge gaps for future research.Pathobiology of Frailty
Frailty biology is a ﬁeld of ongoing research and debate (6).
Putative mechanisms revolve around dysregulation of the
immune, hormonal, and endocrine systems (7)dnotably,
up-regulation of inﬂammatory cytokines (8–10), decreasedof Frailty
es upset the balance between catabolic and anabolic stimuli, respectively, leading to
e is aggravated in patients with insulin resistance and metabolic syndrome. Addition
miting the necessary mobilization of amino acids in times of stress. (Right)
rdiovascular disease, lifelong “wear and tear,” and/or genetic predispositions lead
athways have been proposed. Biological pathways may manifest clinically as slow
henotype of frailty. CRP ¼ C-reactive protein; IL ¼ interleukin; TNF ¼ tumor necrosis
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749testosterone levels (11,12), and insulin resistance (13). This
leads to a catabolic milieu, in which muscle breakdown ex-
ceeds muscle building, leading to a progressive decline in
muscle mass and strength (sarcopenia) (14). Under stressed
conditions, subclinical impairments are unmasked, and a
vicious cycle ensues with physical inactivity and malnutrition
leading to further decline (15,16) (Fig. 1).
The pathobiology of frailty and CVD shares several
commonalities, particularly a consistent correlation with the
inﬂammatory biomarkers interleukin-6 and C-reactive pro-
tein. Just as immune cells and cytokines exert nefarious ef-
fects on the arterial wall to promote atherosclerosis, so too
do they impact cellular senescence and body composition to
promote frailty. Moreover, by causing impairments in
multiple organ systems, subclinical CVD is one of the
important contributors to frailty (17). This biological link
frames the epidemiological data, showing that frailty and
CVD coexist in a large number of individuals (18).
Frailty Assessment Tools
Upward of 20 frailty tools have been developed to measure
frailty (19); owing to a lack of consensus agreement, there is
variability among studies and confusion on which tool to
use. Most tools focus on 1 or more of the 5 core domains
that deﬁne the frailty phenotype: slowness, weakness, low
physical activity, exhaustion, and shrinking. Slowness is
measured by a comfortable-pace gait speed test, weakness by
a maximal handgrip strength test (using a dynamometer),
and other domains by questionnaire or more specialized
instruments. These domains may be considered individually
or combined into a variety of scales (Table 1).
The Fried scale (20) encompasses slowness, weakness, low
physical activity, exhaustion, and shrinking (unintentional
weight loss), with 3 of 5 criteria required for a diagnosis of
frailty. This is the most frequently cited frailty scale and has
been demonstrated to predict mortality and disability in
large cohorts of community-dwelling elders and patients
with CVD. Whether cognition and mood should be
considered as the sixth and seventh domains of frailty or as
modulating factors (i.e., catalyzing the transition from frailty
to overt disability) remains an area of discussion (1,21).
The Short Physical Performance Battery (SPPB) (22,23)
encompasses slowness, weakness, and balance. This is
measured by a series of 3 timed physical performance tests
(gait speed, chair rises, and tandem balance), each is scored
0 to 4 and a total score 5 of 12 is required for a diagnosis of
frailty.
In contrast to these multi-item frailty scales, 5-m gait
speed, and to a lesser extent handgrip strength, has been
advocated as a single-item measure of frailty (24–26) that
often outperforms more elaborate and time-consumingscales. The gait speed test has been shown to have excel-
lent inter-rater reliability (intraclass coefﬁcient 0.88 to 0.96)
and test-retest reliability (intraclass coefﬁcient 0.86 to 0.91)
(27). It is responsive to change, with meaningful improve-
ments in gait speed (estimated at 0.05 to 0.2 m/s [28,29])
predicting positive outcomes on a population level (30) but
not necessarily an individual patient level (31). The walking
distance has varied between 3 and 10 m, although the dis-
tance has little effect on measured speed (32). The 5-m
distance has been adopted by large registries and is a good
balance between allowing patients to achieve a steady
walking speed without eliciting cardiopulmonary symptoms.
The short distance and comfortable pace are well below
cardiopulmonary limitations, making the focus of this test
different than a typical stress test or 6-min walk test.
The aforementioned tools reﬂect the clinical phenotype
of frailty; another school of thought reﬂects the accumu-
lation of deﬁcits (33). Deﬁcits encompass an assortment of
up to 70 symptoms, signs, comorbidities, disabilities, and
frailty traits, which are counted and summed. A simpliﬁed
bedside version has been developed (34). The International
Academy on Nutrition and Aging Frailty Task Force (35)
favored the clinical phenotype approach, stating that
comorbidities and disabilities should be disentangled from
frailty.
Disabilities, broadly deﬁned as difﬁculty or dependency in
carrying out activities of daily living (ADL) or instrumental
ADL, are erroneously interchanged with “frailty” in many
instances. However, disability is more correctly conceptual-
ized as an adverse outcome associated with frailty (e.g., a frail
patient becomes disabled after a myocardial infarction) or as
a separate entity altogether (e.g., a nonfrail patient becomes
disabled after a motor vehicle accident).
Patient heterogeneity precludes the use of a “one size ﬁts
all” scale and cutoff for frailty. There is a ceiling effect
when physical performance scales such as the SPPB are
administered to healthier individuals (more challenging
versions are available) (36), and conversely there is a ﬂoor
effect when the scales are administered to debilitated hos-
pitalized patients (up to 30% have a score of 0). Certain
scales may be effective to screen for frailty, whereas others
may be required to focus on speciﬁc and potentially treat-
able domains. There is justiﬁable reason to consider various
scales, more/less challenging variants of such scales, or
different cutoffs to deﬁne frailty depending on the popu-
lation being studied.
Frailty in CVD: Current Body of Evidence
The prevalence of frailty in community-dwelling older
adults is estimated to be 10% (37), and depending on the
population studied and the frailty assessment tool used, rises
Table 1
Recommended Frailty Assessment Tools
Domain Tool(s) Operational Deﬁnition Common Cutoffs for Frailty
Slowness 5-m gait speed test Patient is positioned behind start line and asked to walk at a comfortable pace past 5-m ﬁnish line; cue to trigger
stopwatch is ﬁrst footfall after start line and ﬁrst footfall after ﬁnish line; repeated 3 times and averaged
Slow: <0.83 m/s (>6s)
Very slow: <0.65 m/s (>7.7 s)
Extremely slow: <0.50 m/s (>10 s)
Weakness Handgrip strength test Patient is asked to squeeze a handgrip dynamometer as hard as possible; repeated 3 times (once with each hand
and then with strongest hand); maximum value is recorded
Men: <30 kg
Women: <20 kg
Knee extensor
strength test
Patient is seated on the dynamometer machine and asked to extend his/her knee against resistance; maximum isotonic
force is recorded
Frailty cutoffs not yet established
Low physical
activity
Physical activity
questionnaire
Many questionnaires have been validated; those that provide a measure of activity in kcal/week
are recommended (e.g., Minnesota Leisure Time Activity, PASE, Paffenbarger Physical Activity
Questionnaire)
Men: <383 kcal/week
Women: <270 kcal/week
Portable accelerometer Patient is asked to wear a portable accelerometer for a period of 1 to 7 days; total kcal expenditure is recorded Frailty cutoffs not yet established
Exhaustion CES-D questionnaire Patient is asked 2 questions: How often in the past week did you feel like everything you did was an effort?/like
you could not get going? (often [i.e., 3 days] or not often [i.e., 0–2 days])
Positive if often is the answer to
either question
Anergia questionnaire Patient is asked 7 questions pertaining to lack of energy over the past month Positive if major criterion “sits around a lot for
lack of energy” þ any 2 of 6 minor criteria
Shrinking Weight loss Self-reported or measured unintentional weight change not due to dieting or exercise 10 lbs in past year
Appendicular
muscle mass
Measured muscle mass in arms and legs using a dual-energy x-ray absorptiometry scan Frailty cutoffs not yet established; general
cutoffs >2 SD from controls
Men: 7.23 kg/height in m2
Women: 5.67 kg/height in m2
Serum albumin Measured serum albumin 3.3 g/dl
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751to 10% to 60% in older adults with CVD (18). In CVD,
frailty confers a 2-fold increase in mortality, an effect that
persists even after adjustment for age and comorbidities. The
relevance and impact of frailty has been demonstrated across
a broad spectrum, including: 1) stable CVD; 2) subclinical
CVD; 3) heart failure; 4) coronary syndromes; 5) cardiac
surgery; and 6) transcatheter aortic valve replacement
(TAVR). These studies are outlined in Table 2 and are
discussed in the following text.
Stable CVD in the Community
Beyond the cross-sectional association between frailty and
CVD, the Women’s Health Initiative Study revealed that
women with coronary artery disease (CAD) were more
likely to develop de novo frailty over 6 years (12% vs. 5%)
(38), and the Health ABC (Health, Aging, and Body
Composition) study showed that older adults with
objectively-measured frailty were more likely to develop
CAD events (3.6% vs. 2.8% per year) (39). Furthermore,
the 3C (Three-City) Study showed that slow gait speed
was highly predictive of cardiovascular mortality (hazard
ratio [HR]: 2.9) but not mortality from cancer or other
causes (HR: 1.0) (25). The EPESE (Established Pop-
ulations for Epidemiologic Studies of the Elderly) Study
similarly showed that impaired mobility was predictive of
CAD-related mortality (relative risk [RR]: 1.8 to 2.2), with
the RR increase being equivalent in magnitude to diabetes
(40). In 2 studies focusing on peripheral arterial disease,
frailty predicted cardiovascular mortality (HR: 2.6 to 11.0)
more so than all-cause mortality (HR: 1.9 to 2.9) (41,42).
Studenski et al. (43) performed a patient-level meta-
analysis of 9 large prospective studies and found that
for every 0.1 m/s increase in gait speed, there was a 10%
improvement in survival. Short-distance gait speed was
a robust yet simple “indicator of vitality that integrates
known and unrecognized disturbances in multiple organ
systems many of which affect survival.” Those who walked at
a speed of 0.8 m/s were predicted to reach an average life
expectancy, whereas those who walked >1.0 m/s exceeded
the average life expectancy (trafﬁc signals at crosswalks are
typically set at a pedestrian walking speed of 1.2 m/s,
reﬂecting the expected lower limit for ambulatory citizens).Subclinical CVD
Before frail patients manifest clinical CVD, they tend to
exhibit subclinical cardiovascular derangements. A seminal
substudy from the Cardiovascular Health Study screened for
subclinical CVD in 4,735 older adults and found that those
who were frail had an increased prevalence of undiagnosed/
subclinical lesions: myocardial injury on echocardiography,
Table 2
Systematic Review of Frailty in Cardiovascular Disease
First Author, Year (Ref. #) N Design Frailty Tool % Frail Main Outcome(s) for Frail vs. Nonfrail
Community dwelling
Studenski, 2011 (43) 34,485 Meta-analysis of elderly in the community Gait speed (2.4–6 m) 32% 12-yr mortality: HR: 0.90 (95% CI: 0.89–0.91) per 0.1-m/s
increase in gait speed
Dumurgier, 2009 (25)
(Three-City Study)
3,208 Prospective cohort of elderly in the
community
Fast-pace gait speed (6 m) Lowest third 5.1-yr mortality: 19% vs. 10 %; HR: 1.4 (95% CI: 1.0–2.0)
*HR: 2.92 for cardiovascular mortality
vs. HR: 1.03 for cancer mortality
Corti, 1996 (40) 4,116 Prospective, multicenter cohort of
elderly in the community
Inability to walk 0.5 miles or
1 ﬂight of stairs
25% 4-yr CAD mortality:
Men 3.5%/yr vs. 1.3%/yr; RR: 1.8 (95% CI: 1.1–3.0)
Women 1.9%/yr vs. 0.6%/yr; RR: 2.2 (95% CI: 1.5–3.5)
4-yr incident CAD:
Men 5.8% vs. 4.5% per yr; RR: 1.2 (95% CI: 0.7–2.1)
Women 5.1% vs. 2.5% per yr; RR: 1.6 (95% CI: 1.3–2.1)
Chin A Paw, 1999 (103) 450 Prospective, multicenter cohort of
elderly men in the community
Chin A Paw scale 13% Prevalent CVD: 62% vs. 28%
3-yr mortality: 50% vs. 18%; OR: 4.1 (95% CI: 1.8–9.4)
Klein, 2005 (104) 2,515 Prospective, multicenter cohort of
elderly and nonelderly in the
community
Klein scale (level 1–4) 53–64 yrs: 0.7%
65–74 yrs: 5%
75–84 yrs: 22%
85 yrs: 53%
Prevalent CVD:
Men: OR: 1.33 (95% CI: 1.06–1.67) per level
Women: OR: 1.43 (95% CI: 1.13–1.82) per level
4-yr mortality: HR: 1.56 (95% CI: 1.27–1.92) per level
Woods, 2005 (38)
(Women’s Health
Initiative Observational
Study)
40,657 Prospective, multicenter cohort of
elderly women in the community
Modiﬁed Fried scale 3 16% Prevalent frailty with vs. without CAD: 17% vs. 7%
Incident frailty with vs. without CAD: 12% vs. 5%;
OR: 1.40 (95% CI: 1.11–1.76)
5.9-yr mortality: OR: 1.71 (95% CI: 1.48–1.97)
Chaves, 2005 (105)
(Women’s Health and
Aging Studies I & II)
670 Prospective, multicenter cohort of
elderly women in the community
Fried scale 3 14% Prevalent CVD: 41% vs. 21%
Bandeen-Roche, 2006 (106)
(Women’s Health and
Aging Studies I & II)
786 Prospective, multicenter cohort of
elderly women in the community
Fried scale 3 11% 3-yr mortality: HR: 6.0 (95% CI: 3.0–12.1)
3-yr severe ADL disability: HR: 15.8 (95% CI: 5.8–42.8)
3-yr nursing home placement: HR: 24.0
(95% CI: 4.5–129.2)
Newman, 2006 (39)
(Health ABC Study)
3,075 Prospective, multicenter cohort of
elderly in the community
Gait speed (400 m) N/A Incident CVD: slowest Q 3.6%/yr vs. fastest Q 2.8%/yr;
HR: 1.61 (95% CI: 1.05–2.45)
5-yr mortality: slowest Q 4.0%/yr vs. fastest Q 1.4%/yr;
HR: 3.23 (95% CI: 2.11–4.94)
Continued on the next page
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Table 2 Continued
First Author, Year (Ref. #) N Design Frailty Tool % Frail Main Outcome(s) for Frail vs. Nonfrail
Subclinical CVD
Newman, 2001 (44)
(Cardiovascular
Health Study)
4,735 Cross-sectional study of elderly in the
community
Fried scale 3 6% Prevalent clinical CVD: 38% vs. 17%; OR: 2.79
(95% CI: 2.12–3.67)
Prevalent subclinical CVD: RWMA, LVH, pre-HTN, low ABI,
carotid stenosis, silent CVA
Elbaz, 2005 (45) 2,572 Prospective, multicenter cohort of
elderly and nonelderly in the community
Fast pace gait speed (6 m) Lowest third CIMT >0.785 mm: mean gait speed 1.47 m/s (vs. 1.61 m/s
in CIMT 0.6 mm); OR: 1.9 (95% CI: 1.4–2.8)
Carotid plaques: mean gait speed 1.50 m/s (vs. 1.57 m/s
in no plaque group); OR: 1.3 (95% CI: 1.0–1.7)
Singh, 2012 (41)
(NHANES)
3,571 Prospective, multicenter cohort of
elderly in the community, focus on those
with PAD
Modiﬁed Fried scale 3 6.4% all
17.5% ABI <0.9
(PAD)
Prevalent frailty with vs. without PAD: 18% vs. 5%; OR: 2.31
(95% CI: 1.08–4.94)
4.9-yr mortality in PAD patients: 52% vs. 21%; HR: 2.88
(95% CI: 1.40–5.96)
4.9-yr CVD mortality in PAD patients: 29% vs. 6%;
HR: 11.02 (95% CI: 3.41–35.60)
McDermott, 2008 (42)
(Walking and Leg
Circulation Study)
444 Prospective multicenter cohort of patients
with PAD (ABI <0.9)
Gait speed <0.76 m/s
(4 m); SPPB
Lowest quartile 4.8-yr mortality: HR: 1.87 (95% CI: 1.06–3.30)
4.8-yr CVD mortality: HR: 2.59 (95% CI: 1.04–6.44)
Cardiac surgery
Aﬁlalo, 2010 (63)
(Frailty ABCs Study)
131 Prospective, multicenter cohort of
elderly patients undergoing cardiac
surgery
Gait speed <0.83 m/s
(5 m) (i.e., >6 s to walk 5 m)
46% In-hospital mortality/morbidity: 35% vs. 13%; OR: 3.05
(95% CI: 1.23–7.54)
Discharge to facility: 46% vs. 20%; OR: 3.19
(95% CI: 1.40–8.41)
Aﬁlalo, 2012 (67)
(Frailty ABCs Study)
152 Prospective, multicenter cohort of
elderly patients undergoing cardiac
surgery
Gait speed <0.83 m/s (5 m)
Fried scale 3
Expanded Fried 3
MSSA subdimensions
46%
20%
In-hospital mortality/morbidity:
Gait speed: AUC 0.68
Fried: AUC 0.60
Expanded Fried: AUC 0.58
MSSA subdimensions: AUC 0.56
Lee, 2010 (64) 3,826 Retrospective cohort of elderly and
nonelderly patients undergoing
cardiac surgery
Ambulation dependence,
ADL disability, or diagnosis
of dementia
4% In-hospital mortality: 15% vs. 5%; OR: 1.8 (95% CI:1.1–3.0)
2-yr mortality: 30% vs. 11%; OR: 1.5 (95% CI: 1.1–2.2)
Discharge to facility: 49% vs. 9%; OR: 6.3
(95% CI: 4.2–9.4)
Sündermann, 2011 (65) 400 Prospective cohort of elderly patients
undergoing cardiac surgery
CAF score 11 50%
(43% moderate,
8% severe)
30-day mortality: 10% vs. 4%; AUC 0.71
Sündermann, 2011 (66) 213 Prospective cohort of elderly patients
undergoing cardiac surgery
CAF score 11 54%
(45% moderate,
9% severe)
1-yr mortality: OR: 1.11 (95% CI: 1.04–1.16) per point
Robinson, 2011 (76) 223 Prospective cohort of elderly patients
undergoing major surgery (34% cardiac
surgery)
Timed up-and-go 15 s 30% Discharge to facility: 67% vs. 8%; OR: 13.0
(95% CI: 5.1–33.0)
Lee, 2011 (107) 262 Prospective cohort of elderly patients
undergoing abdominal aortic
aneurysm surgery
Cross-sectional area of
psoas muscles at L4 by
computed tomography
N/A 90-day mortality: HR: 0.33 (95% CI: 0.16–0.68)
per 1,000-mm2 increase in muscle area
1-yr mortality: 9% tertile 1 vs. 5% tertile 3
3-yr mortality: 21% tertile 1 vs. 13% tertile 3
Continued on the next page
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Table 2 Continued
First Author, Year (Ref. #) N Design Frailty Tool % Frail Main Outcome(s) for Frail vs. Nonfrail
TAVR
Rodés-Cabau, 2010 (70) 345 Retrospective, multicenter cohort
of patients undergoing TAVR
Subjective judgment of
treating physician
25% Procedural complications: no differences except need for
dialysis 7% vs. 1% (p ¼ 0.009)
30-day mortality: 8% vs. 11% (p ¼ 0.54)
8-month mortality: 22% vs. 22% (p ¼ 1.00)
Ewe, 2011 (69) 147 Prospective, multicenter cohort
of patients undergoing TAVR
Fried scale 3 33% 9-month mortality/morbidity: HR: 4.2 (95% CI: 2.0–8.8)
Green, 2012 (71) 102 Cross-sectional study of TAVR (83%), high-risk
AVR (11%), and medically managed AS (5%)
Gait speed <0.5 m/s (4.6 m) 63% Prevalent ADL disability: OR: 1.52 (95% CI: 1.21–1.91)
per 0.1 m/s; AUC 0.81
Green, 2012 (72) 159 Prospective cohort of patients undergoing TAVR Modiﬁed Fried scale >median 50% 30-day mortality/morbidity: nonsigniﬁcant
1-yr mortality: 17% vs. 7%; HR: 3.51 (95% CI: 1.43–8.62)
Schoenenberger, 2012
(73)
119 Prospective cohort of patients undergoing TAVR In-house scale 3/7 50% 6-month ADL change 1: 31.3% vs. 12.1% (OR: 3.34 for
functional decline; OR: 4.21 for functional decline or
death, adjusted for STS)
6-month mortality: 18.6% vs. 3.3%
Stortecky, 2012 (74) 100 Prospective cohort of patients undergoing TAVR
(same cohort as Schoenenberger)
In-house scale 3/7 49% 1-yr mortality: OR: 2.93 (95% CI: 0.93–9.24)
1-yr major cardiovascular and cerebral events:
OR: 4.89 (95% CI: 1.64–14.60); both adjusted for STS
Coronary disease
Purser, 2006 (57) 309 Prospective cohort of elderly patients with
severe CAD admitted to cardiac unit
Fried scale 3
Rockwood scale 1
Gait speed <0.65 m/s
Grip strength <25 kg
Chair rise <7/30 s
27%
63%
50%
50%
56%
6-month mortality:
Fried: 12% vs. 8%; OR: 1.9 (95% CI: 0.6–6.0)
Rockwood: 11% vs. 5%; OR: 1.4 (95% CI: 0.3–5.6)
Gait speed: 14% vs. 4%; OR: 4.0 (95% CI: 1.1–13.8)
Grip strength: 13% vs. 5%; OR: 2.7 (95% CI: 0.7–10.0)
Chair rise: 12% vs. 5%; OR: 1.5 (95% CI: 0.4–5.0)
Ekerstad, 2011 (61) 307 Prospective, multicenter cohort of
elderly patients with NSTEMI admitted to
cardiac or medical unit
CSHA Clinical Frailty Scale 5 49% 30-day mortality/morbidity: 46% vs. 27%; OR: 2.17
(95% C1: 28–3.67)
30-day mortality: 15% vs. 3%; OR: 4.7
(95% CI: 1.7–13.0)
Singh, 2011 (58) 629 Prospective, multicenter cohort of
elderly patients post-PCI
Fried scale 3 21% 3-yr mortality: 28% vs. 6%; HR: 2.74
(95% CI: 1.12–6.71)
Gharacholou, 2012 (60) 629 Cross-sectional analysis of elderly patients
post-PCI (same cohort as Singh)
Fried scale 3 21% SAQ: more physical limitation and lower QOL
(despite same angina frequency)
SF-36: lower PCS and MCS scores
McNulty, 2011 (59) 101 Retrospective, multicenter cohort of elderly
and nonelderly patients post–left main PCI
Subjective judgment of treating
physician (“cachexia/frailty”)
7% 1.5-yr mortality: unadjusted HR: 14.0
(95% CI: 5.4–36.0)
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Table 2 Continued
First Author, Year (Ref. #) N Design Frailty Tool % Frail Main Outcome(s) for Frail vs. Nonfrail
Heart failure
Cacciatore, 2005 (53) 120 Secondary analysis of cohort study of
elderly patients with chronic heart failure
Lachs frailty staging system 15% 12-yr mortality: 94% vs. 69%; HR: 1.62
(95% CI: 1.08–2.45)
Altimir, 2005 (108) 360 Cross-sectional study of elderly patients with
chronic heart failure referred to HF clinic
Altimir scale 42% Prevalent frailty: 42%
Lupón, 2008 (49) 622 Prospective cohort of elderly patients with
chronic heart failure referred to HF clinic
Altimir scale 40% MLWHFQ: 39 vs. 19 (p < 0.001)
HF hospitalization: 21% vs. 13% (p ¼ 0.01)
1-yr mortality: 17% vs. 5%; HR: 2.09
(95% CI: 1.11–3.92)
Volpato, 2008 (54) 92 Prospective cohort of acute patients admitted to
hospital (64% decompensated heart failure)
SPPB admission, discharge N/A Length of stay: þ2.5–4 days for SPPB 0–4 on
admission (þ0.5 day for every SPPB point)
Volpato, 2011 (55) 87 Prospective cohort of acute patients admitted to
hospital (64% decompensated heart failure)
SPPB admission, discharge,
1 month
N/A Incident disability: þ0.24 ADL limitations for SPPB
0–4 at discharge or SPPB decline at follow-up
1-yr mortality or hospitalization: 75% vs. 57%;
OR: 5.38 (95% CI: 1.82–15.9) for SPPB 0–4 vs. 5–12;
HR: 3.59 (95% CI: 1.20–10.0) for SPPB decline
at follow-up
Chiarantini, 2010 (56) 157 Prospective, multicenter cohort of patients
with decompensated heart failure
discharged from cardiac unit
SPPB 51% 15-month mortality:
SPPB 0: 62 per 100 PY; HR: 6.06 (95% CI: 2.19–16.76)
SPPB 1–4: 29 per 100 PY; HR: 4.78
(95% CI: 1.63–14.02)
SPPB 5–8: 17 per 100 PY; HR: 1.95
(95% CI: 0.67–5.70)
SPPB 9–12: 9 per 100 PY; HR: 1 (referent)
Tjam, 2012 (109) 149 Secondary analysis of cohort study of
elderly patients with chronic heart failure
living in long-term care
RAI 2.0 scale N/A 6-month mortality: AUC 0.87
Khan, 2013 (49)
(Health ABC Study)
2,825 Prospective, multicenter cohort of
elderly in the community without baseline
heart failure
Modiﬁed SPPB 2 31% 11-yr incident HF: HR: 1.30 (95% CI: 1.10–1.55)
*Overall incidence 15.9% or 1.8 per 100 PY
Chaudhry, 2013 (110)
(Cardiovascular Health Study)
758 Prospective, multicenter cohort of
elderly in the community with newly
diagnosed heart failure
Gait speed <0.8 m/s (4.6 m)
Grip strength: men: <28.5 kg;
women: <18.5 kg
42% 3.4-yr hospitalization: Gait speed: adjusted
HR: 1.28 (95% CI: 1.06–1.55)
Grip strength: adjusted HR: 1.19 (95% CI: 1.00–1.42)
Rozzini, 2003 (111) 995 Prospective cohort of acute patients
admitted to cardiac unit
Barthel ADL <90
MMSE <18
20% 6-month mortality: 28% vs. 12% vs. 4% if both, either,
or neither criteria present
ABI¼ ankle-brachial index; ADL ¼ activities of daily living; AS¼ aortic stenosis; AUC ¼ area under curve; AVR ¼ aortic valve replacement; CAD ¼ coronary artery disease; CAF ¼ Comprehensive Assessment of Frailty; CIMT ¼ carotid intima media thickness; CSHA ¼ Canadian
Study of Health and Aging; CVA ¼ cerebrovascular accident; CVD ¼ cardiovascular disease; Health ABC ¼ Health, Aging, and Body Composition; HF ¼ heart failure; HR ¼ hazard ratio; HTN ¼ hypertension; LVH ¼ left ventricular hypertrophy; MCS ¼ mental component
summary; MLWHFQ ¼ Minnesota Living With Heart Failure Questionnaire; MMSE ¼ Mini-Mental Status Examination; MSSA ¼ MacArthur Study of Successful Aging; NHANES ¼ National Health and Nutrition Examination Survey; NSTEMI ¼ non–ST-segment elevation
myocardial infarction; OR ¼ odds ratio; PAD ¼ peripheral artery disease; PCI ¼ percutaneous coronary intervention; PCS ¼ physical component summary; PY ¼ person-years; QOL ¼ quality of life; RAI ¼ Resident Assessment Instrument; RR ¼ relative risk; RWMA ¼ regional
wall motion abnormality; SAQ ¼ Seattle Angina Questionnaire; SF-36 ¼ Short-Form 36; SPPB ¼ Short Physical Performance Battery; STS ¼ Society of Thoracic Surgeons; TAVR ¼ transcatheter aortic valve replacement.
JACC
Vol.63,No.8,2014
A
ﬁlalo
et
al.
M
arch
4,2014:747–62
Frailty
in
Cardiovascular
Care
755
Aﬁlalo et al. JACC Vol. 63, No. 8, 2014
Frailty in Cardiovascular Care March 4, 2014:747–62
756brain infarcts on magnetic resonance imaging, abnormal
ankle-brachial index, carotid stenosis, pre-hypertension, and
left ventricular hypertrophy (44). A subanalysis from the 3C
Study showed that those who had slow gait speed were more
likely to have carotid intimal-medial thickening and silent
carotid plaques (45). Subclinical CVD predisposes to “un-
successful aging” (46), often deﬁned as impaired physical or
cognitive functioning and development of clinically manifest
disease (47).
Heart Failure
Frailty is pertinent to the development, manifestations, and
prognosis of heart failure. Frailty may be apparent at the
myocardial organ level by predisposing patients to a greater
extent of myocardial injury and, thus, clinical heart failure in
response to stressors such as coronary ischemia or pressure or
volume overload. Alternatively, frailty may be apparent at
the global multisystem level by predisposing patients with
heart failure to decompensate at a lower threshold and
require more frequent hospitalizations. The person-years
accrued for studies of frailty in the heart failure setting are
greater than those for other cardiac conditions, involving
approximately 2,300 patients with heart failure and up to 12
years of follow-up.
The Health ABC Study followed 2,825 older patients free
of baseline heart failure over a period of 11 years and found
that frailty (as measured by a modiﬁed SPPB) conferred a
30% higher risk of developing new heart failure (48).
Excluding heart failure events in the ﬁrst year did not alter
the results, implying that frailty was not merely capturing
undiagnosed/imminent cardiac dysfunction.
Although traditionally considered a geriatric condition,
frailty was found by Lupón et al. (49) in one-third of
younger patients with heart failure. Because chronic heart
failure is known to perturb skeletal muscle and body
composition (50,51) (giving rise to the phenotype of “cardiac
cachexia” in extreme cases), it is not surprising to observe
a large proportion of younger and older patients with heart
failure exhibiting frailty traits.
Patients with chronic heart failure who were frail had
a higher risk of mortality at 1 year (17% vs. 5%), heart failure
hospitalizations (21% vs. 13%), and impaired quality of life
(49). Chaudhry et al. (52) showed that slow gait speed was
the most powerful predictor of hospitalizations, conferring
a 30% increase; weak grip strength was also predictive,
conferring a 16% increase. In a long-term study by
Cacciatore et al. (53), patients with chronic heart failure who
were frail had a substantially lower probability of surviving
>10 years (6% vs. 31%).
Frailty is also relevant in acute decompensated heart
failure. Volpato et al. (54,55) succeeded in administering theSPPB to patients with recently decompensated heart failure
at different time points (shortly after admission, at discharge,
and 1 month after discharge). A low SPPB score on
admission was associated with prolonged length of stay,
whereas a low SPPB score at discharge was associated with
a higher risk of ADL disability, mortality, or readmission
(odds ratio [OR]: 5.4). In a similar study by Chiarantini
et al. (56), the yearly mortality rates were 62%, 45%, 17%,
and 9% for SPPB scores of 0, 1 to 4, 5 to 8, and 9 to 12,
respectively. The SPPB was responsive to change, with
63% improving versus 20% worsening from admission to
discharge and 50% improving versus 18% worsening from
discharge to 1 month.
Acute Coronary Syndromes and
Percutaneous Coronary Interventions
In a seminal study of 309 elderly patients admitted to a
coronary care unit and found to have multivessel CAD,
Purser et al. (57) found that the prevalence of frailty varied
considerably depending on the tool used: 27% with the Fried
scale, 50% with gait speed <0.65 m/s, and 63% with the
Rockwood scale. Each tool was associated with a trend to-
ward increased 6-month mortality, yet only gait speed was
statistically signiﬁcant (OR: 4.0).
In a study of 629 elderly patients who underwent percu-
taneous coronary intervention at the Mayo Clinic, the
prevalence of frailty was 21% with the Fried scale adminis-
tered before discharge, conferring a signiﬁcant increase
in 3-year mortality (28% vs. 6%; OR: 2.74) (58). Similarly,
“cachexia/frailty” was the most powerful predictor of
18-month mortality (HR: 14.0) (59) in a study of 111 pa-
tients undergoing percutaneous coronary intervention for
unprotected left main disease in the Kaiser Permanente
database.
Gharacholou et al. (60) further showed that, despite a
similar severity of angina between frail and nonfrail
patients, those who were frail had lower physical functioning
and quality of life. Frailty exerted a greater impact on quality
of life than comorbidities. Ekerstad et al. (61) explored the
relationship between frailty and comorbidities in patients
with non–ST-segment elevation myocardial infarction and
showed that 79% of frail patients had at least 1 severe co-
morbidity. The OR for frailty to predict mortality was
exponentially higher when the comorbidity burden was
moderate to severe.
The studies of Ekerstad, Purser, and Lupón all showed
that frail patients were less aggressively managed compared
with their nonfrail counterparts; whether this is for better or
for worse remains unclear. They were less likely to receive
angiotensin-converting enzyme inhibitors (71% vs. 81%)
and beta-blockers (63% vs. 80%), less likely to be admitted
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referred for cardiac catheterization (15% vs. 46%) or coro-
nary artery bypass surgery (9% vs. 16%).
Cardiac Surgery
Cardiac surgery is an inherently relevant setting for frailty
because surgery represents an iatrogenic physiological
stressor to which the patient’s resiliency will determine their
post-operative course. Surgeons have been performing de
facto clinical frailty assessments termed the “eyeball test” or
the “end of the bed-o-gram” for quite some time. More
recently, investigators have examined the role of objective
frailty tools to predict post-operative outcomes, and even the
lay media has been attracted by this prospect (62). The
utility of frailty to prospectively guide surgical decisions and
improve outcomes has yet to be explicitly tested.
The Frailty ABCs (Frailty Assessment Before Cardiac
Surgery) prospective study showed that slow 5-m gait speed
was associated with a 3-fold increase in post-operative
mortality or major morbidity (OR: 3.1) (63). A walking
time of 6 s or longer (<0.83 m/s) was selected as the optimal
cutoff based on receiver-operating characteristic analysis.
Importantly, gait speed contributed incremental value above
the Society for Thoracic Surgeons risk score (area under the
curve 0.70 for risk score alone vs. area under the curve 0.74
for risk score plus gait speed). Patients with slow gait speed
and a high risk score had a 43% incidence of mortality/
morbidity, whereas those with normal gait speed and a low
to intermediate risk score had a 6% incidence. There was
a trend toward interaction for female patients and those
undergoing aortic valve replacement (AVR), both of which
had a markedly greater RR when frailty was present.
Studies by Lee et al. (64) and Sündermann et al. (65,66)
showed that pre-operative frailty was associated with post-
operative mortality at 30 days and 1 to 2 years. These
2 studies differed in the frailty scales used, and as a result, in
the reported prevalence of frailty. Lee et al. (64) retrospec-
tively reviewed data from theMaritime Heart Center Cardiac
Surgery Registry and deﬁned frailty as ambulation depen-
dence, ADL disability, or diagnosed dementia. This deﬁni-
tion represented disability more than frailty and yielded a low
4% prevalence of frailty (mixed elderly and nonelderly
cohort). Sündermann et al. (65,66) deﬁned frailty as an
aggregate of 35 criteria, which yielded a 50% prevalence of
frailty. The data from Aﬁlalo et al. (67) showed a 46%
prevalence of frailty using gait speed versus 20% using the
Fried scale and a low 5% prevalence of ADL disability; the
single measure of gait speed outperformed other scales in
predicting outcomes.
The presence of frank disability is infrequent in the
general cardiac surgery population, in part because disabledpatients are less likely to be referred for such a surgery.
Therefore, disability scales for basic ADL are insensitive to
screen elderly patients in this context. Higher-level disability
scales such as the Nagi scale are more sensitive and better
predict outcomes. An interaction between frailty and
disability has been reported, with the prognostic effect of
frailty diminishing in patients who have progressed to the
more advanced stage of disability (67).
In addition to predicting post-operative mortality and
morbidity, 3 studies showed that frail patients were less
likely to be discharged home and were more likely to require
rehabilitation and/or institutionalization after cardiac surgery
(OR: 3.2 to 13.0).
Thus, it is evident that frail patients who undergo cardiac
surgery have higher rates of post-operative mortality,
morbidity, prolonged length of stay, and need for discharge
to facilities. It is not evident whether frail patients who
undergo less invasive intervention (or no intervention) have
improved outcomes, although this is at times extrapolated.
For the time being, a more prudent extrapolation may be
that the risks and beneﬁts of cardiac surgery should
be carefully weighed in frail patients, ideally with a multi-
disciplinary heart team, and if indicated, should proceed
with thorough pre-operative optimization and heightened
post-operative surveillance.
Transcatheter Aortic Valve Replacement
TAVR was initially developed for patients with severe aortic
stenosis (AS) who were considered “too frail for surgery;”
thus, the concept of frailty has been intimately linked to
TAVR. Patients referred for TAVR typically have advanced
age, multiple comorbidities, and a prevalence of frailty as
high as 63%. Frailty is 1 of the “missing parameters” not
captured by traditional risk scores (68) that are relied upon
by clinicians as gatekeepers to TAVR. Few studies have been
published in the past 2 years, limited to approximately 100
to 150 patients each, and larger studies are underway.
Although this was not the primary aim of their study,
Ewe et al. (69) found that one-third of patients undergoing
TAVR were frail according to the Fried scale and that frailty
was among the most powerful predictors of death, myocar-
dial infarction, stroke, or heart failure at 9 months (HR:
4.2). Frailty was not a signiﬁcant predictor when deﬁned
according to the physician’s subjective judgment in the
earlier study by Rodés-Cabau et al. (70).
Green et al. (71,72) presented the experience at Columbia
University and surprisingly showed that frailty was predictive
of 1-year mortality (17% if frail vs. 7% if not frail; HR: 3.5)
but not the composite of 30-day mortality or morbidity. The
lack of 30-day event prediction was attributed to “adequacy of
the standard selection process,” although it should be noted
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who had been screened out to substantiate the adequacy of
the selection process and the absolute number of events was
low. Furthermore, the trends toward greater risk in frail
patients (especially for major bleeding, major vascular com-
plications, and length of stay) were concerning. The increase
in C-statistic from 0.73 to 0.77 and the net reclassiﬁcation
index of 0.24 were in the clinically meaningful range, yet
conﬁdence intervals were wide.
Between 19% and 35% of patients were unable to complete
the short-distance gait speed test. This is a sizeable propor-
tion of nonwalkers, larger than the <10% generally reported
for other cardiac cohorts, which may reﬂect the heavy burden
of comorbidity and disability in patients undergoing TAVR.
Not being able to complete the gait speed test is an indicator
of advanced frailty or perhaps even disability because non-
walkers have weaker grip strength, lower albumin levels, and
more ADL disabilities. Low albumin levels and ADL dis-
abilities were the strongest predictors in their TAVR cohort.
A gait speed of 0.50 m/s was selected as the optimal cutoff
based on receiver-operating characteristic analysis, slower
than the 0.65 to 0.85 m/s cutoffs reported for other cardiac
cohorts. The authors commented that>80% of their patients
would have been considered frail if these traditional cutoffs
had been used, supporting the notion that adapted cutoffs are
required to achieve reasonable discrimination.
This is in slight contrast to the TAVR experience at Bern
University (73,74), in which the vast majority of patients
were able to complete the timed-up-and-go test (which re-
quires standing up from a chair, walking 3 m, and turning
around) and 61% of patients were able to do so faster than
the usual cutoff of 20 s. Their frailty scale consisted of
timed-up-and-go, mobility limitation, basic ADL disability,
instrumental ADL disability, mini-mental status examina-
tion, and mini-nutritional assessment. Frailty was predictive
of a 3- to 4-fold increase in functional decline at 6 months
(measured by basic ADL disabilities) and major cardiac and
cerebral adverse events at 1 year. There was a trend for frailty
and all-cause mortality, which was stronger at 30 days
compared with 1 year, although the number of events was
small.
Synthesizing the evidence surrounding frailty in TAVR,
2 critical questions arise: ﬁrst, are the standard frailty
assessment tools (gait speed, even with adapted cutoffs, grip
strength, and Fried scale) valid in this severely ill and often
debilitated population or are these traits too ubiquitous, such
that we should be relying on markers of more advanced
frailty and frank disability (inability to walk, low albumin,
ADL disability) to better discriminate risk? Second, does
frailty increase the risk of short-term morbidity after TAVR
(as it does in cardiac surgery) or does the less invasive natureof the transcatheter procedure mitigate this risk? In both
cardiac surgery and TAVR, the rate of technical success
remains high and the risk of intraprocedural mortality low in
frail patients.The Use of Frailty in Clinical Practice
There are many scenarios in day-to-day clinical practice in
which frailty assessment can contribute valuable prognostic
information and assist the clinicians in deﬁning optimal care
pathways for their patients. Ideally, frailty is not a reason
to withhold care but rather a means of structuring care in a
more patient-centered fashion.
A guiding principle is that frailty, disability, and comor-
bidity are inter-related but distinct entities (75). A second
principle is that there is no deﬁnitive gold standard test for
frailty, but rather an assortment of tools that reﬂect 1 or more
domains of frailty. Multidomain tools do not necessarily
provide incremental value above single-domain tools, and ease
of implementation may be an important factor for adoption.
A third principle is that frailty is a continuous spectrum,
and speciﬁc cutoffs used to dichotomize frailty status in 1
group of patients may not be applicable in another group.
The tools recommended in Table 1 provide a (nonre-
strictive) framework to improve consistency and compara-
bility among studies. For investigators seeking to test new or
modiﬁed tools, they are encouraged to also use 1 of the
recommended tools as a comparator and to conﬁrm the
ﬁndings in a validation cohort before reporting.
High-Yield Clinical Scenarios for Assessment
of Frailty in Cardiovascular Medicine
Consideration for cardiac surgery. Frailty assessment tools
should be employed in the pre-operative period; at a mini-
mum, 5-m gait speed is a simple and powerful measure of
frailty supported by prognostic data. However, it is prema-
ture to assume that frailty should determine eligibility for
surgery at the individual patient level. Until data are available
to prove a direct role for frailty in determining treatment, it
is recommended to integrate frailty with other proven risk
factors and risk models for decision making.
The timing of frailty assessment may be in the inpatient
setting just before the surgery or in the outpatient setting,
providing there is no intercurrent change or prolonged delay
(arbitrarily>1month) between the assessment and surgery. The
choice of when to assess frailty tends to be logistically driven
depending on feasibility and work ﬂow at the given center.
Pre-operative optimization via amultidisciplinary approach
is key to counteract the multiple physiological impairments
(e.g., cardiac, neurological, muscular, respiratory, renal) that
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frailty (76). Establishing a heart team and involving the
appropriate consultants are instrumental in this regard.
Prompt recognition and treatment of complications are pri-
mordial; deconditioning and delirium are 2 complications that
merit special attention because of their insidious and devas-
tating course. Cardiac rehabilitation may potentially improve
frailty, and although this has yet to be proven, may ultimately
serve to facilitate surgical recovery for frail elderly patients.
Patients may beneﬁt, for example, if cardiac rehabilitation is
initiated before a planned procedure and then continued af-
terward, with aerobic and strength training alongside nutri-
tional and educational components.
Consideration for TAVR. Because patient selection con-
tinues to be a central and often challenging issue, there is
hope that frailty can be used to pre-select high-risk patients
with AS who are best served by TAVR rather than surgical
AVR. Proving this hypothesis has not been straightforward,
particularly because the majority of patients referred for
TAVR are frail and the usefulness of frailty (or any other risk
factor) becomes limited when it is endemic. Moreover,
because the TAVR procedure induces less physiologic stress
compared with surgery, it is unclear whether frailty will
predict post-procedural outcomes similarly in TAVR and
surgery.
The role of frailty assessment in TAVR programs may
ultimately prove to be in identifying who is not frail and thus
appropriate for conventional AVR. At the other end of the
spectrum, the role of frailty assessment may be in identifying
who is extremely frail and/or disabled and thus appropriate
for medical management without intervention. The latter
patient typically exhibits 1 or more features of cachexia,
severe weakness, inability to ambulate, dementia, and ADL
dependencies. Anecdotally, balloon aortic valvuloplasty has
been used to allow for rehabilitation and improvements in
heart failure as a bridge to TAVR.
Stable or recently stabilized heart failure or CAD. Once
identiﬁed in the inpatient or outpatient setting, frail
patients may be excellent candidates for cardiac rehabilita-
tion (targeting frail patients may be 1 strategy to overcome
the underuse of cardiac rehabilitation in general), longitu-
dinal heart function clinics, and comprehensive geriatric
assessment (77). The latter may include evaluation by ex-
perts in nutrition, physical function, cognition, psycho-
geriatrics, and social support; each of which represents an
area of potential vulnerability for frail patients and a blind
spot for most cardiovascular practitioners who are not
accustomed to dealing with these issues. This blind spot is
increasingly being addressed at the educational level within
cardiology curricula and continuing medical education
programs.Controversies and Future Research Questions
Deﬁning the optimal tool set to measure frailty is a high
priority. We must ﬁrst determine whether there is incre-
mental value in using multi-item scales such as Fried as
opposed to single-item measures such as 5-m gait speed
(57,67,78,79). We must also determine the appropriate
cutoff for each tool and patient group, particularly for gait
speed (>10 cutoffs have been proposed ranging from 0.5 to
1.0 m/s). This underscores the need to validate frailty tools
and cutoffs in the population of interest rather than
extrapolating results from other studies.
The ongoing FRAILTY-AVR multicenter study
(NCT01845207) is comparing different frailty tools to
determine which is most predictive in high-risk patients
with AS undergoing AVR and TAVR. The Society for
Thoracic Surgeons Adult Cardiac Surgery Database is
collecting 5-meter gait speed data to deﬁne its
value across a broad sample of patients undergoing
cardiac surgery. The CoreValve U.S. pivotal trial and
PARTNER II (Placement of Aortic Transcatheter Valves)
trial have integrated frailty assessment in all eligible patients.
The SILVER-AMI Trial (NCT01755052) is evaluating the
impact of frailty alongside other risk factors in older adults
hospitalized with acute myocardial infarction. Many other
CVD trials have begun considering frailty.
There is an impetus to develop more robust frailty tools.
Existing tools are limited in the measurement of physical
activity and energy expenditure (80,81); portable pedom-
eters and actigraphy-based tools are being investigated for
this purpose (82). Whereas most tools capture muscle
strength, muscle mass is only indirectly measured by
weight loss. Weight loss is a ﬂawed measure of muscle
mass because excess adiposity may mask low muscle
massdtermed “sarcopenic obesity” (83,84). In a study of
elderly patients with cancer, 7.5% of patients were found to
be underweight, whereas 46.8% were sarcopenic (85).
Muscle mass is a predictor of frailty and functional decline
(86,87) and can be reliably measured by computed to-
mography, magnetic resonance, or dual-isotope x-ray ab-
sorptiometry (88).
Exciting translational research is seeking to gain mecha-
nistic insights into the pathobiology of frailty and, in doing
so, is fueling the development of frailty therapeutics and
elusive frailty biomarkers. Biomarkers of senescence such as
telomere length are not correlated with frailty (89). Other
biomarkers have been correlated with frailty but remain
nonspeciﬁc: C-reactive protein, interleukin 6, tumor necrosis
factor alpha, neutrophil count, D-dimer, plasminogen acti-
vator inhibitor-1, testosterone, insulin-like growth factor-1,
albumin, vitamin D, lymphocyte count, and memory/naive
CD8 T-cell ratio. Thus, efforts to develop a speciﬁc
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760biomarker or panel of biomarkers for frailty have been un-
successful to date (90).
With the accrual of diagnostic and prognostic data in
CVD cohorts, we are now on the horizon of therapeutic
trials to deﬁne how to best care for our frail cardiac patients
(91,92). Interventions may be divided into those that:
1) direct frail patients toward less invasive therapeutic
pathways; 2) monitor frail patients more closely to promptly
detect and avert adverse events; 3) treat frail patients with
therapies to improve their clinical or subclinical comorbid-
ities; or 4) treat frail patients with therapies to reverse or
reduce their intrinsic frailty.
A controversial question is to what extent a patient’s
frailty is intrinsic or related to a speciﬁc comorbidity that
can be treated (so-called “reversible” comorbidity-related
frailty) (93). Some suggest that when the degree of
frailty is out of proportion to the burden of comorbidity,
it is intrinsic and less likely to improve after removal of
the comorbidity. This suggestion is an oversimpliﬁcation
because the manifestations of frailty are not only inﬂu-
enced by comorbidity but also by a host of other modu-
lating factors (e.g., cognition, mood, compliance, and
social support).
The most widely studied interventions to improve frailty
are exercise training, nutritional supplementation, testos-
terone replacement, and comprehensive geriatric assessment/
management (94–99). Testosterone levels are associated
with frailty (100), and the beneﬁts of testosterone replace-
ment appear to be consistent across sexes (96). Other in-
terventions are aimed at improving the delivery and
coordination of care for frail elders (101). Ideally, frailty
should be identiﬁed before a cardiac intervention is immi-
nent. Regardless of the intervention, the treatment of frail
patients should emphasize patient-centered outcomes such
as functional status and quality of life (102).
Conclusions
There is a substantial body of evidence to support the
utility of frailty assessment in patients with diverse forms
of CVD. The value of frailty as a prognostic marker is well
demonstrated (with risk ratios that often exceed 2 and
dwarf juxtaposed predictors in multivariable models). The
value of frailty in guiding cardiovascular care and as a
therapeutic target is beginning to emerge and should be
expanded in future applications to improve patient out-
comes. The frailty assessment tools outlined should facil-
itate this task by promoting a validated tool set that will
allow us to compare and synthesize the results of different
studies and provide a frame of reference when evaluating
novel frailty markers.Reprint requests and correspondence: Dr. Jonathan Aﬁlalo,
Divisions of Cardiology and Clinical Epidemiology, Jewish Gen-
eral Hospital, McGill University, 3755 Cote Sainte Catherine
Road, E-222, Montreal, Quebec H3T 1E2, Canada. E-mail:
jonathan.aﬁlalo@mcgill.ca.
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